Catalyst Wire Dossier Catalyst Wire Dossier

Tumor-infiltrating lymphocytes (TILs) therapy

tumor-infiltrating lymphocytes
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Tumor-infiltrating lymphocytes (TILs) therapy, covering 2024-09-05 to 2024-09-05. Get the full timeline:

Most recent: Clinical Trial Update: "Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1]

See pricing